BR112012003280A2 - composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. - Google Patents

composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.

Info

Publication number: BR112012003280A2
Authority: BR; Brazil
Prior art keywords: compound; disease; treating; pharmaceutical composition; oral administration
Prior art date: 2009-08-24

Application number

BR112012003280A

Other languages

English (en)

Inventor

Maria Hojer Astrid

Kateb Jens

Gundorf Drewes Pernille

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-24

Filing date

2010-08-23

Publication date

2017-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43628463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012003280(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-23 Application filed by H Lundbeck As filed Critical H Lundbeck As

2017-05-23 Publication of BR112012003280A2 publication Critical patent/BR112012003280A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BR112012003280A 2009-08-24 2010-08-23 composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. BR112012003280A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200900950		2009-08-24
PCT/DK2010/050216 WO2011023194A2 (en)	2009-08-24	2010-08-23	New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Publications (1)

Publication Number	Publication Date
BR112012003280A2 true BR112012003280A2 (pt)	2017-05-23

Family

ID=43628463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112012003280A BR112012003280A2 (pt)	2009-08-24	2010-08-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.

Country Status (32)

Country	Link
US (3)	US20120189697A1 (pt)
EP (1)	EP2470166B1 (pt)
JP (1)	JP2013502446A (pt)
KR (1)	KR20120065328A (pt)
CN (1)	CN102639117A (pt)
AU (1)	AU2010289022B2 (pt)
BR (1)	BR112012003280A2 (pt)
CA (1)	CA2769872A1 (pt)
CL (1)	CL2012000457A1 (pt)
CO (1)	CO6612204A2 (pt)
CR (1)	CR20120058A (pt)
DK (1)	DK2470166T3 (pt)
DO (1)	DOP2012000050A (pt)
EA (1)	EA021321B1 (pt)
ES (1)	ES2427628T3 (pt)
GE (1)	GEP20135950B (pt)
HR (1)	HRP20130819T1 (pt)
IL (1)	IL217914A0 (pt)
MA (1)	MA33598B1 (pt)
ME (1)	ME01602B (pt)
MX (1)	MX2012002199A (pt)
NZ (1)	NZ598083A (pt)
PL (1)	PL2470166T3 (pt)
PT (1)	PT2470166E (pt)
RS (1)	RS52959B (pt)
SG (1)	SG178325A1 (pt)
SI (1)	SI2470166T1 (pt)
SM (1)	SMT201300108B (pt)
TN (1)	TN2012000038A1 (pt)
UA (1)	UA105057C2 (pt)
WO (1)	WO2011023194A2 (pt)
ZA (1)	ZA201201360B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200932233A (en)	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
KR101820181B1 (ko) *	2010-04-30	2018-02-28	다케다 야쿠힌 고교 가부시키가이샤	장용성 정제
BR112012027782A2 (pt)	2010-04-30	2016-08-02	Takeda Pharmaceutical	tablete entérico
CN104146953A (zh) *	2014-07-24	2014-11-19	李雪梅	一种氢溴酸沃替西汀注射液
CN104610195B (zh) *	2015-01-30	2017-06-27	上虞京新药业有限公司	沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) *	2015-05-13	2020-07-05	H Lundbeck As	فيروتيوكسيتين بيروجلوتامات
EP3184104B1 (en)	2015-12-23	2018-09-12	Hexal AG	Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
EP3184102A1 (en)	2015-12-23	2017-06-28	Hexal AG	Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
SG11201810644TA (en)	2016-07-01	2018-12-28	H Lundbeck As	Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2018065348A1 (en)	2016-10-05	2018-04-12	Hexal Ag	Novel enteric-coated tablet comprising vortioxetine
CN112006995A (zh) *	2020-08-14	2020-12-01	石药集团中奇制药技术（石家庄）有限公司	一种氢溴酸伏硫西汀片的制备方法
CN113350348B (zh) *	2020-11-05	2022-03-01	东南大学	一种1-二苯甲基-4-甲基哌嗪类化合物在制备保护肠道屏障完整性药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9514842D0 (en) *	1995-07-20	1995-09-20	Smithkline Beecham Plc	Novel formulation
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6866146B2 (en)	2001-10-09	2005-03-15	Christian M. Heesch	Protective case for string instruments
WO2006069030A1 (en) *	2004-12-20	2006-06-29	Collegium Pharmaceutical, Inc.	Pharmaceutical compositions for sleep disorders
KR101533268B1 (ko) *	2005-05-12	2015-07-03	애브비 바하마스 리미티드	아폽토시스 촉진제
WO2007015270A2 (en) *	2005-08-02	2007-02-08	Lupin Limited	Novel controlled release compositions of selective serotonin reuptake inhibitors
ES2432102T3 (es) *	2006-06-16	2013-11-29	H. Lundbeck A/S	Compuestos con actividad combinada en SERT, 5-HT3 y 5-HT1A
TW200848411A (en)	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) *	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

2010
- 2010-08-23 US US13/388,750 patent/US20120189697A1/en not_active Abandoned
- 2010-08-23 RS RS20130404A patent/RS52959B/en unknown
- 2010-08-23 EA EA201290116A patent/EA021321B1/ru not_active IP Right Cessation
- 2010-08-23 AU AU2010289022A patent/AU2010289022B2/en not_active Ceased
- 2010-08-23 PT PT108054149T patent/PT2470166E/pt unknown
- 2010-08-23 CA CA2769872A patent/CA2769872A1/en not_active Abandoned
- 2010-08-23 SI SI201030343T patent/SI2470166T1/sl unknown
- 2010-08-23 MX MX2012002199A patent/MX2012002199A/es active IP Right Grant
- 2010-08-23 EP EP10805414.9A patent/EP2470166B1/en not_active Revoked
- 2010-08-23 DK DK10805414.9T patent/DK2470166T3/da active
- 2010-08-23 KR KR1020127004405A patent/KR20120065328A/ko not_active Application Discontinuation
- 2010-08-23 UA UAA201203101A patent/UA105057C2/uk unknown
- 2010-08-23 GE GEAP201012633A patent/GEP20135950B/en unknown
- 2010-08-23 NZ NZ598083A patent/NZ598083A/xx not_active IP Right Cessation
- 2010-08-23 ES ES10805414T patent/ES2427628T3/es active Active
- 2010-08-23 JP JP2012525884A patent/JP2013502446A/ja active Pending
- 2010-08-23 PL PL10805414T patent/PL2470166T3/pl unknown
- 2010-08-23 ME MEP-2013-99A patent/ME01602B/me unknown
- 2010-08-23 WO PCT/DK2010/050216 patent/WO2011023194A2/en active Application Filing
- 2010-08-23 CN CN2010800376999A patent/CN102639117A/zh active Pending
- 2010-08-23 BR BR112012003280A patent/BR112012003280A2/pt not_active IP Right Cessation
- 2010-08-23 SG SG2012008868A patent/SG178325A1/en unknown
2012
- 2012-01-25 TN TNP2012000038A patent/TN2012000038A1/en unknown
- 2012-02-02 IL IL217914A patent/IL217914A0/en unknown
- 2012-02-07 CR CR20120058A patent/CR20120058A/es unknown
- 2012-02-17 CO CO12028578A patent/CO6612204A2/es not_active Application Discontinuation
- 2012-02-22 CL CL2012000457A patent/CL2012000457A1/es unknown
- 2012-02-23 DO DO2012000050A patent/DOP2012000050A/es unknown
- 2012-02-23 ZA ZA2012/01360A patent/ZA201201360B/en unknown
- 2012-03-21 MA MA34709A patent/MA33598B1/fr unknown
2013
- 2013-09-02 HR HRP20130819AT patent/HRP20130819T1/hr unknown
- 2013-09-30 SM SM201300108T patent/SMT201300108B/xx unknown
2015
- 2015-02-04 US US14/613,693 patent/US20150150867A1/en not_active Abandoned
- 2015-10-19 US US14/886,333 patent/US20160256398A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CO6612204A2 (es)	2013-02-01
CR20120058A (es)	2012-04-26
JP2013502446A (ja)	2013-01-24
DOP2012000050A (es)	2012-07-31
SG178325A1 (en)	2012-03-29
AU2010289022B2 (en)	2013-03-14
CL2012000457A1 (es)	2013-01-25
RS52959B (en)	2014-02-28
AU2010289022A1 (en)	2012-03-08
CN102639117A (zh)	2012-08-15
SI2470166T1 (sl)	2014-03-31
PT2470166E (pt)	2013-10-02
EA201290116A1 (ru)	2012-06-29
HRP20130819T1 (en)	2013-09-30
MX2012002199A (es)	2012-03-16
WO2011023194A2 (en)	2011-03-03
WO2011023194A3 (en)	2011-12-01
EP2470166A2 (en)	2012-07-04
ME01602B (me)	2014-09-20
KR20120065328A (ko)	2012-06-20
TN2012000038A1 (en)	2013-09-19
PL2470166T3 (pl)	2013-11-29
NZ598083A (en)	2013-08-30
EA021321B1 (ru)	2015-05-29
US20120189697A1 (en)	2012-07-26
MA33598B1 (fr)	2012-09-01
US20150150867A1 (en)	2015-06-04
DK2470166T3 (da)	2013-09-08
UA105057C2 (uk)	2014-04-10
IL217914A0 (en)	2012-03-29
US20160256398A1 (en)	2016-09-08
GEP20135950B (en)	2013-10-25
ZA201201360B (en)	2013-05-29
CA2769872A1 (en)	2011-03-03
SMT201300108B (it)	2013-11-08
EP2470166B1 (en)	2013-08-14
ES2427628T3 (es)	2013-10-31

Publication	Publication Date	Title
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0818680A2 (pt)	2017-05-02	composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BRPI0814666A2 (pt)	2017-05-09	composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BRPI0914918A2 (pt)	2015-10-20	forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI0916689A2 (pt)	2015-11-17	composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI0814503A2 (pt)	2017-05-16	composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0816320A2 (pt)	2015-03-24	Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0922174A2 (pt)	2015-12-29	preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BRPI1014865A2 (pt)	2016-05-03	"composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0922566A2 (pt)	2017-03-28	polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0818483A2 (pt)	2015-04-14	Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0922173A2 (pt)	2015-12-29	preparação farmacêutica, e, método para preparar uma preparação farmacêutica

Legal Events

Date	Code	Title
2017-06-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2021-07-13	B350	Update of information on the portal [chapter 15.35 patent gazette]